Lung cancer in 'never-smokers': beyond EGFR mutations and EGFR-TK inhibitors.
Burns
Timothy F
TF
Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA.
Rudin
Charles M
CM
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D066246:ErbB Receptors / Q000235:genetics; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D009154:Mutation; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D012907:Smoking / Q000009:adverse effects
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases